Delta-Fly Pharma,Inc. [4598.T]
TOKYO, May 28 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) announced today that patient enrollment for the phase II portion of its clinical trial comparing cancer microenvironment agent DFP17,729 with TS-1 (TS-1) has been completed.
The trial, conducted jointly with ChemoFa Corporation, involves patients undergoing pancreatic cancer treatment beyond their third-line therapy. The adaptive seamless design of the study allows for efficient validation of overall survival (OS).
Upon confirmation of OS superiority in the phase II part, the number of cases in the phase III portion will be adjusted accordingly. Should OS superiority be confirmed, DFP17,729's additional benefits would be validated, potentially offering a more patient-friendly cancer microenvironment improvement agent due to its oral administration, high safety profile, and economic efficiency.
For further inquiries, interested parties should contact Delta-Fly Pharma's management department via the company’s IR website.
🟢 Confidence: High AI-translated content.